---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-080304"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2025-08-19T23:59:59+00:00"
generated_at: "2026-05-17T11:23:54.089385+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Iovance's Amtagvi receives Health Canada approval for advanced melanoma

## Summary
- Health Canada issued NOC/c for Amtagvi (lifileucel) for unresectable/metastatic melanoma after anti-PD-1 and targeted therapy.
- First marketing authorization outside the U.S.; first T cell therapy approved for a solid tumor cancer in Canada.
- Approval based on Phase 2 C-144-01 trial ORR and DOR by IRC; results published in 2022 and 2025 journals.
- Iovance expects to authorize first Canadian treatment center within next few months; advancing ex-U.S. strategy.
- Amtagvi is also being investigated in frontline advanced melanoma (Phase 3 TILVANCE-301) and other solid tumors.

## SEC filing metadata
- accession: 0001104659-25-080304
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2025-08-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465925080304/0001104659-25-080304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465925080304/tm2523802d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-080304
- JSON: https://secwatch.observer/filing/0001104659-25-080304.json
- Plain text: https://secwatch.observer/filing/0001104659-25-080304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.